Literature DB >> 6457309

Effects of zimelidine and desipramine on serotonin and noradrenaline uptake mechanisms in relation to plasma concentrations and to therapeutic effects during treatment of depression.

A Aberg-Wistedt, K G Jostell, S B Ross, D Westerlund.   

Abstract

The selective inhibitors of neuronal 5-hydroxytryptamine (5-HT) and noradrenaline (NA) uptake, zimelidine and desipramine, were compared in a double blind crossover study of 40 inpatients with endogenous depression. The clinical effects of these two drugs and some biochemical variables related to the monoamine systems were studied during 4 weeks' treatment. Patients with a low pretreatment level of 5-hydroxyindoleacetic acid (5-HIAA) in the cerebrospinal fluid (CSF) (less than 20 ng/ml) responded significantly better to zimelidine treatment than those with a high pretreatment level (greater than 20 ng/ml). In the group treated with desipramine no difference in therapeutic outcome was obtained between patients with low and high pretreatments levels of 5-HIAA in the CSF. Attempts to correlate the steady state plasma concentrations of zimelidine, norzimelidine and desipramine with the therapeutic effect were unsuccessful. The plasma concentration of norzimelidine demonstrated a significant (P less than 0.05) positive correlation with age. The mean value of the uptake of 14C-5-HT in the patient's platelets, when measured before the treatment, was significantly (P less than 0.05) lower than found in a control group. Zimelidine, mainly via its metabolite norzimelidine, caused a pronounced inhibition of uptake of 14C-5-HT in platelets, decrease in whole blood 5-HT and inhibition of accumulation of 14C-5-HT in rat hypothalamic synaptosomes incubated in the patients plasma. Desipramine produced a slight inhibition of accumulation of 14C-5-HT in rat synaptosomes, but a marked inhibition of uptake of 14C-5-HT in the patient's platelets and a decrease in whole blood 5-HT. The accumulation of 3H-NA in rat synaptosomes incubated in the patient's plasma was strongly inhibited by desipramine treatment but only slightly affected by zimelidine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6457309     DOI: 10.1007/bf00432735

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  (Z)-dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl) propene (h 102/09), a new selective inhibitor of the neuronal 5-hydroxytryptamine uptake.

Authors:  S B Ross; S O Ogren; A L Renyi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-08

2.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

3.  Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect.

Authors:  I P Lapin; G F Oxenkrug
Journal:  Lancet       Date:  1969-01-18       Impact factor: 79.321

4.  Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine.

Authors:  A Carlsson; H Corrodi; K Fuxe; T Hökfelt
Journal:  Eur J Pharmacol       Date:  1969-03       Impact factor: 4.432

5.  A rapid accurate procedure for the determination of serotonin in whole human blood.

Authors:  A Yuwiler; S Plotkin; E Geller; E R Ritvo
Journal:  Biochem Med       Date:  1970-04

6.  Zimelidine: a therapeutic and pharmacokinetic study in depression.

Authors:  A Coppen; V A Ramo Rao; C Swade; K Wood
Journal:  Psychopharmacology (Berl)       Date:  1979-06-21       Impact factor: 4.530

7.  "Serotonin depression"--a biochemical subgroup within the affective disorders?

Authors:  M Asberg; P Thorén; L Träskman; L Bertilsson; V Ringberger
Journal:  Science       Date:  1976-02-06       Impact factor: 47.728

8.  Tricyclic antidepressant agents. I. Comparison of the inhibition of the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices and crude synaptosome preparations of the midbrain-hypothalamus region of the rat brain.

Authors:  S B Ross; A L Renyi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

9.  Inhibition of the neuronal uptake of 5-hydroxytryptamine and noradrenaline in rat brain by (Z)- and (E)-3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridyl) allylamines and their secondary analogues.

Authors:  S B Ross; A L Renyi
Journal:  Neuropharmacology       Date:  1977-01       Impact factor: 5.250

10.  The antidepressant efficacy of zimelidine and maprotiline.

Authors:  S A Montgomery; S J Rani; R McAuley; D Roy; D B Montgomery
Journal:  Acta Psychiatr Scand Suppl       Date:  1981
View more
  10 in total

Review 1.  [Therapy resistance to antidepressants. Definition, prevalence, predictors, and interventional possibilities].

Authors:  H-J Möller
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

2.  Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites.

Authors:  R Malmgren; A Aberg-Wistedt; L Bertilsson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl.

Authors:  G P Luscombe; N A Slater; M B Lyons; R D Wynne; M L Scheinbaum; W R Buckett
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 4.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

5.  The effect of PK5078, a new serotonin uptake inhibitor, on serotonin levels and uptake in human platelets, following administration to healthy volunteers.

Authors:  M Kenny; T J Lenehan; R Lambe; I Brick; A Darragh; C Maulet
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Effects of a single oral dose of 3-cyano-imipramine on serotonin uptake and content of platelets in healthy volunteers.

Authors:  M Kenny; T J Lenehan; R Lambe; A Darragh; I Brick; L M Omer
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

7.  Pharmacokinetic study of zimelidine using a new GLC method.

Authors:  G Caillé; E Kouassi; C de Montigny
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

8.  Inhibitors of serotonin and noradrenaline uptake in human plasma after withdrawal of zimelidine and clomipramine treatment.

Authors:  S B Ross; A Aberg-Wistedt
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

Review 9.  Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R C Heel; P A Morley; R N Brogden; A A Carmine; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-09       Impact factor: 9.546

10.  Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster.

Authors:  Danielle Gulick; David T Chau; Jibran Y Khokhar; Ree Dawson; Alan I Green
Journal:  Psychiatry Res       Date:  2014-05-04       Impact factor: 3.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.